ClinicalTrials.gg
Not yet recruitingNCT07261696Updated Dec 3, 2025

The Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia

An interventional study of Exercise in Fibromyalgia and Autonomic Dysfunction, sponsored by Nigde Omer Halisdemir University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Nigde Omer Halisdemir University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Fibromyalgia with a site in Turkey — 50 open to participants now, 54 under way, none of them phase 3. Fibromyalgia · Turkey.

Planned enrollment
53rd of 104
51 · median 52
Started
2025
with 26 others
No phase
102 of 195
25 open now
Primary completion
2026-12
later than 35 of 53 live
Registered
151st of 195
by date

Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 53rd largest by planned enrollment of the 104 interventional ones that give a count, is one of 27 that started in 2025, is one of 102 with no phase, reaches primary completion later than 35 of the 53 other live ones, and was the 151st registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

50 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Fibromyalgia with a site in Turkey, or all of them as a file.
02

Study summary

Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and psychological symptoms. Autonomic nervous system (ANS) dysfunction, marked by increased sympathetic and reduced parasympathetic activity, is considered one of its possible mechanisms. Although exercise is recommended in treatment, low motivation and fatigue often limit participation. Therefore, inspiratory muscle training (IMT), which targets the respiratory muscles, is seen as an easy-to-apply alternative.This randomized, controlled, double-blind study will be conducted at Niğde Ömer Halisdemir University Hospital. Fifty-one women aged 18-65 years who meet the 2010/2016 ACR criteria for fibromyalgia will be randomly assigned to three groups: training (30% of maximal inspiratory pressure), sham (0-10%), and control (no training). ANS functions will be assessed using heart rate variability and the COMPASS-31 questionnaire. Pain, sleep quality, fatigue, anxiety, depression, and respiratory muscle strength will also be evaluated. Training will be performed with the Powerbreathe® device twice daily for six weeks.The study aims to investigate the effects of IMT on ANS functions in fibromyalgia and to explore its relationship with symptoms such as pain, fatigue, sleep disturbances, anxiety, and depression.

Read the detailed description

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and psychological symptoms, the exact cause of which remains unclear. Autonomic nervous system (ANS) dysfunction, characterized by increased sympathetic activity and decreased parasympathetic tone, is considered one of the major pathophysiological mechanisms of the disease. Exercise is a strongly recommended non-pharmacological approach in the treatment of fibromyalgia; however, low motivation, fatigue, and poor adherence often limit the applicability of conventional aerobic or resistance exercise programs. Therefore, inspiratory muscle training (IMT), which specifically targets the respiratory muscles, is considered an alternative method that is easy to apply and may have regulatory effects on ANS function.

This randomized, controlled, double-blind, and prospective study will be conducted in the Rheumatology and Cardiology Clinics of Niğde Ömer Halisdemir University Training and Research Hospital. A total of 51 female participants aged 18-65 years who meet the 2010/2016 American College of Rheumatology (ACR) criteria for fibromyalgia will be randomly assigned to three groups: the training group (30% maximal inspiratory pressure [MIP]), the sham group (0-10% MIP), and the control group (no training). ANS functions will be evaluated by heart rate variability (HRV) and the COMPASS-31 questionnaire. Pain will be assessed using the Visual Analog Scale and pressure pain threshold; sleep quality by the Pittsburgh Sleep Quality Index; fatigue by the Modified Fatigue Impact Scale; anxiety and depression by the Hospital Anxiety and Depression Scale; and respiratory muscle strength by the Powerbreathe® K5 device. Training will be performed using the Powerbreathe® Classic device twice daily, seven days per week, for six weeks.

The primary aim of this study is to evaluate the effects of inspiratory muscle training on autonomic nervous system functions in patients with fibromyalgia. Secondarily, the effects of this training on symptoms such as pain, fatigue, sleep disturbances, anxiety, and depression, as well as the relationship between these symptoms and changes in ANS activity, will be investigated.

03

Conditions studied

  • Fibromyalgia
  • Autonomic Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged between 18 and 65 years old,
  • Have been diagnosed with fibromyalgia according to the 2010/2016 ACR criteria,
  • Be female,
  • Have moderate pain lasting at least 3 months and defined as at least 30 mm on the 0-100 mm visual analogue scale (VAS).

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic heart disease,
  • Current use of narcotic drugs,
  • History of asthma or other chronic respiratory diseases,
  • Pregnancy,
  • Diabetes, kidney, adrenal, pituitary or thyroid disorders,
  • History of serious neurological or psychiatric disorders (e.g. mania, psychosis, suicidal tendencies, bipolar disorder, schizophrenia, autism spectrum disorders),
  • Neurodegenerative diseases (e.g. Parkinson's, Alzheimer's, Huntington's disease),
  • Head trauma, migraine,
  • Presence of active cardiac implants.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Study Group

    Training at 30% of maximum inspiratory pressure for 6 weeks, 2 sessions per day, 7 days a week

    Other: Exercise

  • Sham comparator
    Sham group

    Training at 0-10% of maximum inspiratory pressure for 6 weeks, 2 sessions per day, 7 days a week

    Other: Exercise

  • No intervention
    Control group

    No Intervention

Interventions

  • OtherExercise

    Inspiratory muscle training program will be applied to the study and sham group for 7 days/6 weeks.

06

What researchers measure

Primary outcomes

  1. Autonomic nervous system- HRV

    The procedure will be performed using a 24-hour ECG Holter monitor.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  2. Autonomic Nervous System- COMPASS-31

    The Composite Autonomic Symptom Score-31 questionnaire will be used.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

Secondary outcomes

  1. Pain- Visual Analogue Scale

    Visual Analogue Scale will be used.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  2. Pain- Pressure Pain Treshold

    The pain threshold will be assessed using a standard pressure algometer

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  3. Sleep- Pittsburgh sleep quality index

    Pittsburgh sleep quality index questionnaire will be used.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  4. Fatigue- Modified Fatigue Impact Scale

    Modified Fatigue Impact Scale will be used.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  5. Anxiety and Depression- Hospital Anxiety and Depression Scale

    Hospital Anxiety and Depression Scale questionnaire will be used.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

  6. Maximal inspiratory pressure

    Measurements will be taken using the PowerBreathe K5 MIP device to determine the exercise load.

    Time frame: At the time participants joined the study and after the 6-week training for the intervention and sham groups, and 6 weeks later for the control group.

07

Study locations

1 site
  • Niğde Ömer Halisdemir Üniversitesi
    Niğde, Niğde Province 51200, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartEst.
Dec 5, 2025
Primary completionEst.
Dec 5, 2026
CompletionEst.
Dec 5, 2026
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07261696
Lead sponsor
Nigde Omer Halisdemir University
Responsible party
Gürkan Demirtas (PhD, Nigde Omer Halisdemir University) — Principal investigator
First posted
Dec 3, 2025
Start date
Dec 5, 2025 (estimated)
Primary completion
Dec 5, 2026 (estimated)
Completion
Dec 5, 2026 (estimated)
Last update
Dec 3, 2025

Study contacts

Gürkan Demirtaş, PhD
Contact
gurkandemirtas@ohu.edu.tr
+90 388 311 2105
Gürkan Demirtaş, PhD
principal investigator · Niğde Ömer Halisdemir University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion